Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations

Journal of Pharmacological and Toxicological Methods

Volumn 70, Issue 2, 2014, Pages 188-194

  Jin, Xiannu ^a   Luong, Thu Lan ^a   Reese, Necole ^a   Gaona, Heather ^a   Collazo Velez, Vanessa ^a   Vuong, Chau ^a   Potter, Brittney ^a   Sousa, Jason C ^a   Olmeda, Raul ^a   Li, Qigui ^a   Xie, Lisa ^a   Zhang, Jing ^a   Zhang, Ping ^a   Reichard, Greg ^a   Melendez, Victor ^a   Marcsisin, Sean R ^a   Pybus, Brandon S ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Anti malarial drug development; Caco 2; MDCK; MDCK MDR1; Permeability; Primaquine Chloroquine interaction

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; FUROSEMIDE; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN; PRAZOSIN; PRIMAQUINE; PROPRANOLOL; QUINIDINE; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CACO 2 CELL LINE; CELL BASED PERMEABILITY ASSAY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG RESEARCH; DRUG SCREENING; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MALE; MDCK CELL LINE; MOUSE; NONHUMAN; TANDEM MASS SPECTROMETRY; ABSORPTION; ANIMAL; C3H MOUSE; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PERMEABILITY; PROCEDURES;

ABSORPTION, PHYSIOLOGICAL; ANIMALS; ANTIMALARIALS; CACO-2 CELLS; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; DOGS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, INBRED C3H; PERMEABILITY; TANDEM MASS SPECTROMETRY;

EID: 84907052818     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2014.08.002     Document Type: Article

References (25)

1. Alving A.S., Arnold J., Hockwald R.S., Clayman C.B., Dern R.J., Beutler E., et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. Journal of Laboratory and Clinical Medicine 1955, 46:301-306.
2. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications 1991, 175:880-885.
3. Barrett P.J., Emmins P.D., Clarke P.D., Bradley D.J. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996, 313:525-528.
4. Brandsch M., Ganapathy V., Leibach F.H. H(+)-peptide cotransport in madin-darby canine kidney cells: Expression and calmodulin-dependent regulation. The American Journal of Physiology 1995, 268(3 Pt 2):F391-F397.
5. Gaertner L.S., Murray C.L., Morris C.E. Transepithelial transport of nicotine and vinblastine in isolated Malpighian tubules of the tobacco hornworm (Manduca sexta) suggests a P-glycoprotein-like mechanism. The Journal of Experimental Biology 1998, 201:2637-2645.
6. Hellinger E., Veszelka S., Toth A.E., Walter F., Kittel A., Bakk M.L., et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. European Journal of Pharmaceutics and Biopharmaceutics 2012, 82:340-351.
7. Horio M., Chin K.V., Currier S.J., Goldenberg S., Williams C., Pastan I., et al. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. Journal of Biological Chemistry 1989, 264:14880-148804.
8. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., et al. Mdck (madin-darby canine kidney) cells: A tool for membrane permeability screening. Journal of Pharmaceutical Sciences 1999, 88(1):28-33.
9. Kharasch E.D., Hoffer C., Altuntas T.G., Whittington D. Quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl. Journal of Clinical Pharmacology 2004, 44:224-233.
10. Lennernas H., Palm K., Fagerholm U., Artursson P. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. International Journal of Pharmaceutics 1991, 127:103-107.
11. Milner E., McCalmont W., Bhonsle J., Caridha D., Cobar J., Gardner S., et al. Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols. Malaria Journal 2010, 9:51.
12. Misfeldt D.S., Hamamoto S.T., Pitelka D.R. Transepithelial transport in cell culture. Proceedings of the National Academy of Sciences of the United States of America 1976, 73:1212-1216.
13. Mori N., Yokooji T., Murakami T. Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats. Pharmazie 2008, 63:241-244.
14. Na-Bangchang K., Congpuong K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. The Tohoku Journal of Experimental Medicine 2007, 211:99-113.
15. Pimentel D., Tort M., D'Anna L., Krawic A., Berger J., Rossman J., et al. Ecology of increasing disease: population growth and environmental degradation. BioScience 1998, 48:817-826.
16. Pukrittayakamee S., Tarning J., Jittamala P., Charunwatthana P., Lawpoolsri S., Lee S.J., et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrobial Agents and Chemotherapy 2014, 58:3354-3359.
17. Rautio J., Humphreys J.E., Webster L.O., Balakrishnan A., John P., Keogh J.P., et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:786-792.
18. Putnam W.S., Pan L., Tsutsui K., Takahashi L., Benet L.Z. Comparison of bidirectional cephalexin transport across mdck and caco-2 cell monolayers: Interactions with peptide transporters. Pharmaceutical Research 2002, 19(1):27-33.
19. Ritchie E.C., Block J., Nevin R.L. Psychiatric side effects of mefloquine: applications to forensic psychiatry. The Journal of the American Academy of Psychiatry and the Law 2013, 41:224-235.
20. Sousa J.C., Milner E., Carroll D., McCalmont W., Gardner S., Moon J., et al. The use of a prodrug approach to minimize potential CNS exposure of next generation quinoline methanols while maintaining efficacy in in vivo animal models. European Journal of Drug Metabolism and Pharmacokinetics 2014, http://dx.doi.org/10.1007/s13318-013-0162-9 (in press).
21. Tang F., Horie K., Borchardt R.T. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?. Pharmaceutical Research 2002, 19:765-772.
22. Taub M.E., Podila L., Ely D., Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metabolism and Disposition 2005, 33:1679-1687.
23. van Riemsdijk M.M., Sturkenboom M.C., Pepplinkhuizen L., Stricker B.H. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. Journal of Clinical Psychiatry 2005, 66:199-204.
24. Volpe D.A. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. Journal of Pharmaceutical Sciences 2008, 97:712-725.
25. Wang Q., Rager J.D., Weinstein K., Kardos P.S., Dobson G.L., Li J., et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. International Journal of Pharmaceutics 2005, 288:349-359.